Cutaneous microvascular effects of mid-term hormone replacement therapy in healthy postmenopausal women. A prospective placebo controlled trial

Journal des Maladies Vasculaires

Volumn 28, Issue 4, 2003, Pages 190-193

  Chabbert Buffet, N ^a   Bonnin, P ^b   Levy B ^b   Abdoucheli Baudot, N ^a   Tribout, L ^a   Gaitz, J P ^a   Vayssairat, M ^a  

^a HÔPITAL TENON   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Hormone replacement therapy; Laser Doppler velocimetry; Microcirculation

Indexed keywords

ESTRADIOL; PLACEBO; PROMEGESTONE;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; BODY POSITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOOT; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HYPEREMIA; LASER DOPPLER FLOWMETRY; MEASUREMENT; MICROVASCULATURE; NORMAL HUMAN; PARAMETER; POSTMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN BLOOD FLOW; SKIN BLOOD VESSEL; SUPINE POSITION; VASOMOTOR REFLEX;

DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LASER-DOPPLER FLOWMETRY; MICROCIRCULATION; MIDDLE AGED; POSTMENOPAUSE; PROMEGESTONE; PROSPECTIVE STUDIES; SKIN;

EID: 0142197847     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. MANSON JE, MARTIN KA. Postmenopausal hormone-replacement therapy. N Engl J Med, 2001; 345: 34-40.
2. MENDELSOHN ME, KARAS RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med, 1999; 340: 1801-11.
3. MOSCA L, COLLINS P, HERRINGTON DM et al. Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation, 2001; 104: 499-503.
4. SAMAAN SA, CRAWFORD MH. Estrogen and cardiovascular function after menopause. J Am Coll Cardiol, 1995; 26: 1403-10.
5. ALEXANDER KP, NEWBY LK, HELLKAMP AS et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol, 2001; 38: 1-7.
6. HULLEY S, GRADY D, BUSH T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1988; 280: 605-13.
7. ARORA S, VEVES A, CABALLERO AE et al. Estrogen improves endothelial function. J Vasc Surg, 1998; 27: 1141-7.
8. BROOKS-ASPLUND EM, KENNEY WL. Chronic hormone replacement therapy does not alter resting or maximal skin blood flow. J Appl Physiol (United States), 1998; 85: 505-10.
9. HAENGGI W, LINDER HR, BIRKHAEUSER MH et al. Microscopic findings of the nail-fold capillary dependence on menopausal status and hormone replacement therapy. Maturitas, 1995; 22: 37-46.
10. LIM SC, CABALLERO AE, ARORA S et al. The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab, 1999; 84: 4159-64.
11. REIS SE, HOLUBKOV R, CONRAD SMITH AJ et al. Coronary micro-vascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J, 2001; 141: 735-41.
12. HASSAN AAK, TOOKE JE. Mechanism of the postural vasoconstrictor response in the human foot. Clin Sci, 1988; 75: 379-87.
13. TUR E, YOSIPOVITCH G, BAR-ON Y. Skin reactive hyperemia in diabetic patients. A study by laser Doppler flowmetry. Diabetes Care, 1991; 14: 958-62.
14. VUILLEUMIER P, DECOSTERD D, MAILLARD M et al. Postischemic forearm skin reactive hyperemia is related to cardiovascular risk factors in a healthy female population. J Hypertens, 2002; 20: 1753-7.
15. HASSAN AAK, CARTER G, TOOKE JE. Postural vasoconstriction in women during the normal menstrual cycle. Clin Sci, 1990; 78: 39-47.
16. PETERSON LR, EYSTER D, DAVILA-ROMAN VG et al. Short-term oral estrogen replacement therapy does not augment endothelium-independent myocardial perfusion in postmenopausal women. Am Heart J, 2001; 142: 641-7.